Yin, Tao

Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Ren, Z., Xu, J., Bai, Y., Xu, A., Cang, S., Du, C., Li, Q., Lu, Y., Chen, Y., Guo, Y., et al. (2021) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,124

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 545

Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice

Li, L., Song, L., Liu, X., Yang, X., Li, X., He, T., Wang, N., Yang, S., Yu, C., Yin, T., et al. (2017) · ACS Nano

RNA Interference and Gene DeliveryCRISPR and Genetic Engineering

Cited by 244

METTL3 promotes pancreatic cancer proliferation and stemness by increasing stability of ID2 mRNA in a m6A-dependent manner

Chen, J., Zhang, H., Xiu, C., Gao, C., Wu, S., Bai, J., Shen, Q., & Yin, T. (2023) · Cancer Letters

RNA modifications and cancerCancer-related molecular mechanisms research

Cited by 71

Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma

CHEN, Q., CHENG, P., YIN, T., HE, H., YANG, L., WEI, Y., & CHEN, X. (2012) · International Journal of Molecular Medicine

Mesenchymal stem cell researchBacterial Cancer Therapy

Cited by 27